And… that’s a wrap on #TropMed22! Thank you to the 4,000 in person folks and 700 virtual folks that were able to join us. We look forward to seeing you in Chicago for TropMed23!

Did a lot take place at #TropMed22? See for yourself: https://t.co/AFCiArwBpy

It's our final day at @ASTMH #TropMed22! At her poster presentation, Elizabeth Chiyende, Zambia-based social behavior change specialist, explains PATH's PAMO Plus project's use of interpersonal communications approaches to boost uptake of malaria services. https://t.co/SAkwepEVcA

Are you attending the 2022 @ASTMH Annual Meeting next week? Come check out our sessions on #NTDs, #malaria, and pandemic preparedness and visit us at Booth #222. Learn more: https://t.co/5obg9hPP4K #TropMed22

.⁦@WL_Hamilton⁩ cultured strains of P Falciparum over 2+ years to look at evolution in real-time. Turns out the parasite is *sneaky*! Check out his poster at 5362 at ⁦@ASTMH⁩ #TropMed22 to find out more about what he discovered. #IamTropMed

Thank you for everyone who joined us for the Partnership for Vivax Elimination #TropMed22 side event to discuss results of the Tafenoquine Roll-out STudy (TRuST) and optimizing P. vivax—a complex and persistent type of #malaria—to pave the way for malaria elimination. #EndMalaria

We had an amazing time at the @ASTMH 2022 Annual Meeting. Pretty neat to see these numbers, including 115 countries represented and 1,507 first-time attendees #TropMed22 #IamTropMed

ICYMI, the Mwele Malecela Mentorship Programme for Women in NTDs was announced at #TropMed22 by Dr. Matshidiso Moeti, Regional Director of the WHO Regional Office for Africa. Applications will open in December. https://t.co/czsETnjolQ

Malaria News: One dose of a monoclonal antibody safely protected healthy, non-pregnant adults from #malaria infection during an intense six-month malaria season in Mali, Africa, an #NIAID-funded clinical trial found: https://t.co/oXHi1nk9Rg @ASTMH #TropMed22

Together in person at #TropMed22 for the first time in three years! @ASTMH provides an opportunity for PATH and our global partners to come together to share our wide breadth of #malaria control and elimination efforts rooted in deep technical expertise. https://t.co/SAkwepWw48

New editorial by Umberto D’Alessandro, M.D., Ph.D.: "Monoclonal Antibodies against Malaria" #TropMed22 https://t.co/YP7aHTa4mU

We took advantage of @ASTMH #TropMed22 being held in Seattle to show some of our malaria partners around our product development shop! During the tour the group learned about our progress on several next-generation health innovations, including those to detect and treat #malaria.

#TropMed22 attendees -- Session recordings are now available to view. In-person attendees have all access. Livestream attendees have access to livestream sessions, plus the option to upgrade to all access or buy malaria, NTDs and virology sessions. https://t.co/bPvq0TeI4j

Dengue kills 20,000 to 25,000 people every year – and the number of cases is on the rise. A warming planet and increasing urbanization put more people at risk of dengue and other flaviviruses. #TropMed22 What can be done? Watch to learn:

Presentando en el @ASTMH #TropMed22 dos trabajos del @IMUSFQ sobre la vigilancia genómica de COVID en 🇪🇨 y sobre el análisis inmunológico de Reinfecciones de COVID (RICOVA) con @DrShaziaRuybal @MEBaldeon

Congrats to Dr Bernard Pécoul, founder of DNDi, for receiving the @ASTMH Clara Southmayd Ludlow Medal at #TropMed22 tonight in Seattle! The medal rewards 40 years of leadership in tropical medicine. For Dr Pécoul it is “ultimately about the patients.” #IamTropMed

Unable to attend #TropMed22? We have webcasts for purchase. Choose from all access, the livestream sessions or the malaria, NTDs or virology sessions. https://t.co/bT1fIKEx9a

Flaviviruses like dengue infect millions each year, but Asia experiences nearly 3/4 of the global burden. #TropMed22

In this phase 2 trial in Mali, an antimalarial monoclonal antibody (CIS43LS) at the higher dose (40 mg per kilogram) was approximately 88% effective at preventing P. falciparum infection as compared with placebo. #TropMed22 https://t.co/UGeBHOPhKY

Research Scientist, Justin Millar, presented a poster at #TropMed22 on using gravity models to estimate facility-level catchment populations and #malaria incidence rates from health surveillance systems. More on PATH's presence at @ASTMH: https://t.co/SAkwepEVcA